Tempus AI, Inc. — Company profile
Healthcare · Health Information Services · United States
Last price 72.22 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 13.03B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Details
| Name | Tempus AI, Inc. |
| Sector | Healthcare |
| Industry | Health Information Services |
| Employees | 3800 |
| Founded | 2015 |
| Ipo Date | 2024-06-14 |
| Ceo | Eric Lefkofsky |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 37.00 |
| Isin | US88023B1035 |
| Cusip | 88023B103 |
| Cik | 1717115 |
| Sic | 7370 |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
Key executives
| Name | Title |
|---|---|
| Eric P. Lefkofsky J.D. | Co-Founder, Chief Executive Officer, President and Chairman |
| James Rogers | Chief Financial Officer |
| Erik Phelps | Executive Vice President and Chief Administrative and Legal Officer |
| Andrew Polovin | Chief Legal Officer |
| Ryan M. Bartolucci CPA | Chief Accounting Officer |
| Shane Colley | Chief Technology Officer |
| Dr. Kate A. Sasser Ph.D. | Chief Scientific Officer |
| Elizabeth Krutoholow | Vice President of Investor Relations and Competitive Intelligence |
| Christina Antoniou | Senior Vice President and Head of Corporate Development |
| Stacey Kraft | Chief People Officer |
Contact
| Address | 600 West Chicago Avenue, Suite 510, Chicago, Illinois 60654, United States |
| Phone | 800 976 5448 |
| Website | https://www.tempus.com |